POTS in adolescents: criteria, specific features and outcomes

In adolescents, POTS heart-rate criteria differ from those used in adults, and pediatric data on diagnosis and outcomes remain incomplete.

11 sources
6 min read
Clinical review
Verified 8 November 2026

Key points

Criteria commonly used for ages 12–19 require a sustained heart-rate increase of at least 40 beats per minute within 10 minutes of moving upright (standing up or being tilted upright), with chronic orthostatic symptoms, no orthostatic hypotension and other causes ruled out. ^{[1, 10, 2, 3]}
The pediatric review by Boris and Moak points out that the validity of the 40 bpm threshold for an active stand test, as opposed to a tilt-table test, is still debated, and that diagnostic criteria are poorly defined before age 12. A comparative study in young people published in 2025 found that tilt discriminated better than a 5-minute standing test in its sample; it does not settle the question for all protocols. ^{[1, 4]}
Described symptoms include lightheadedness, palpitations, tremor, weakness, blurred vision and fatigue; headaches, digestive problems and cognitive difficulties are also reported. In young people, school and sport are part of the context to take into account. ^{[1, 5]}
Outcome data differ between cohorts: a US follow-up survey with a 34% response rate reported complete resolution in 19%, while a retrospective Chinese cohort (121 young people enrolled, 115 followed up, median age 12) reported a cumulative symptom-free proportion of 48.4% at one year and 85.6% at six years; the six-year figure rests on few children still followed at that point (mean follow-up 18.7 months) and is very uncertain. These figures are not directly comparable. ^{[6, 7]}
When ME/CFS or post-exertional malaise is present, approaches to physical activity cannot automatically be carried over from general reconditioning programs: NICE (the UK’s National Institute for Health and Care Excellence) advises against fixed increases in exercise in ME/CFS in its NG206 guideline. ^[8]

What is specific to adolescence

Criteria commonly used for ages 12–19

Assessment in young people

Course and outcomes

What is still debated

Observational data suggest that symptoms can improve over time, but complete resolution is not universal. In the US study by Bhatia et al. (Mayo Clinic), 172 of 502 former patients diagnosed between ages 13 and 18 answered a survey conducted on average 5.4 years after diagnosis; 19% reported complete resolution, 51% improvement with ongoing symptoms and 16% intermittent symptoms. ^[6]

A retrospective, single-center Chinese cohort (121 children and adolescents enrolled, 115 followed up, median age 12, mean follow-up 18.7 months) reported, after conventional interventions, an estimated cumulative symptom-free proportion of 48.4% at one year and 85.6% at six years. The six-year figure rests on few children still followed at that point (mean follow-up 18.7 months) and is very uncertain. About half of these children (median age 12) were under 12, an age for which criteria remain poorly defined. ^{[7, 1]}

Activity, school and post-exertional malaise

What is still debated

Exercise training has been studied in POTS, but the evidence remains scarce, particularly in young people. Orthostatic intolerance, including POTS, can accompany ME/CFS; NICE lists it among its symptoms. NICE describes post-exertional malaise as a worsening of symptoms, often delayed by hours or days, that is out of proportion to the activity and followed by prolonged recovery. ^{[11, 8]}

The NICE NG206 guideline on ME/CFS states that people with ME/CFS should not be offered exercise programs based on fixed, incremental increases in activity (including graded exercise therapy as defined in the guideline). This recommendation concerns ME/CFS, not POTS in general; it does not automatically apply to everyone with POTS, or to post-exertional malaise on its own without a diagnosis of ME/CFS. ^[8]

POTS and hypermobility in young people

The possible coexistence of POTS and joint hypermobility in children and adolescents, and the assessment of hypermobility using specific pediatric criteria, are covered in Hypermobility in children and Hypermobility and POTS. Coexistence does not mean that one condition causes the other.

Differences between countries

References and level of evidence

Boris JR, Moak JP. Pediatric Postural Orthostatic Tachycardia Syndrome: Where We Stand. Pediatrics, 150(1), e2021054945 2022. DOI: 10.1542/peds.2021-054945. PMID: 35773520.(evidence synthesis)
Limitations: Narrative review; highlights gaps in pediatric thresholds and data. Population: pediatric clinical review. Read: full text (open access, Pediatrics).
Declared conflicts of interest: The authors declare no conflicts of interest
Raj SR, Fedorowski A, Sheldon RS. Diagnosis and management of postural orthostatic tachycardia syndrome. CMAJ, 194(10), E378–E385 2022. DOI: 10.1503/cmaj.211373. PMID: 35288409.(evidence synthesis)
Limitations: Narrative synthesis, not a formal national guideline; protocol differences. Population: clinical review and practical recommendations. Read: full text (cmaj.ca).
Declared conflicts of interest: All three authors declare research funding, honoraria or consulting activities; Raj and Sheldon also declare expert-witness work or patents
Haute Autorité de santé. Parcours de soins de l'adulte avec des symptômes prolongés de la Covid-19. HAS (French National Authority for Health), care pathway guide, approved April 11, 2024 2024.(guideline or consensus)
Limitations: Does not cover POTS as a whole outside post-COVID cases; post-COVID care pathway guide. Population: adults and adolescents aged 15 or over with prolonged post-COVID symptoms. Read: full text.
Declared conflicts of interest: The group's public declarations of interest were reviewed by HAS and judged compatible
Stewart JM, Medow MS. Can standing replace upright tilt table testing in the diagnosis of postural tachycardia syndrome (POTS) in the young?. Clinical Autonomic Research, 35(2), 257–266 2025. DOI: 10.1007/s10286-024-01080-x. PMID: 39592549.(observational study)
Limitations: Small sample, ROC criteria derived from this single sample, standing test of at least 5 minutes (most participants could not stand for 10 minutes). Population: comparison of 36 young people with POTS and 39 controls; 5-minute standing test versus 5- and 10-minute tilt. Read: abstract.
Declared conflicts of interest: Not reviewed in the part of the source that was read
Raj SR, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): Priorities for POTS care and research from a 2019 National Institutes of Health Expert Consensus Meeting - Part 2. Autonomic Neuroscience, 235, 102836 2021. DOI: 10.1016/j.autneu.2021.102836. PMID: 34246578.(guideline or consensus)
Limitations: Not a cohort study; several measurement and research needs remain unresolved. Population: expert consensus and review of knowledge gaps. Read: abstract.
Declared conflicts of interest: Not reviewed in the part of the source that was read
Bhatia R, Kizilbash SJ, Ahrens SP, Killian JM, Kimmes SA, Knoebel EE, Muppa P, Weaver AL, Fischer PR. Outcomes of Adolescent-Onset Postural Orthostatic Tachycardia Syndrome. Journal of Pediatrics, 173, 149–153 2016. DOI: 10.1016/j.jpeds.2016.02.035. PMID: 26979650.(observational study)
Limitations: 34% response rate, self-report, respondents mostly female; possible non-response bias. Population: follow-up survey of a Mayo cohort; 172 respondents out of 502 people contacted. Read: abstract only.
Declared conflicts of interest: Not reviewed in the part of the source that was read
Tao C, Lu W, Lin J, et al. Long-Term Outcomes of Children and Adolescents With Postural Tachycardia Syndrome After Conventional Treatment. Frontiers in Pediatrics, 7, 261 2019. DOI: 10.3389/fped.2019.00261. PMID: 31316954.(observational study)
Limitations: Single center, non-randomized treatment, study-specific criteria for symptom resolution. Population: cohort of 121 pediatric patients; mean follow-up 18.7 months, range 14–74 months. Read: full text.
Declared conflicts of interest: No conflicts declared in the section consulted
NICE. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206). NICE guideline 2021.(guideline or consensus)
Limitations: Not a POTS guideline; relevant only to ME/CFS and the associated post-exertional malaise. Population: children, young people and adults with suspected or diagnosed ME/CFS. Read: online recommendations (nice.org.uk), published October 29, 2021.
Declared conflicts of interest: Institutional document; group declarations according to NICE
Vernino S. et al. Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1. Autonomic Neuroscience, 235, 102828 2021. DOI: 10.1016/j.autneu.2021.102828. PMID: 34144933.(guideline or consensus)
Limitations: Expert consensus; heterogeneous pathophysiology; limited epidemiological data. Population: literature synthesis and NIH expert meeting; adults and children. Read: full text.
Declared conflicts of interest: Competing interests declared individually in the article (consulting, grants, patents).
Sheldon RS, Grubb BP II, Olshansky B, et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Heart Rhythm, 12(6), e41–e63 2015. DOI: 10.1016/j.hrthm.2015.03.029. PMID: 25980576.(guideline or consensus)
Limitations: 2015 recommendations; several areas rest on a low level of evidence. Population: international consensus of cardiovascular and autonomic societies. Read: full text (HRS PDF).
Declared conflicts of interest: Industry ties declared by several authors (appendix 1: Medtronic, Boston Scientific, St. Jude, Lundbeck, Biotronik…); NHLBI funding
Schiweck N, Langer K, Maier A, Vilser D, Spiegler J. Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS). Clinical Autonomic Research, 36(1), 3–16 2026. DOI: 10.1007/s10286-025-01172-2. PMID: 41225175.(evidence synthesis)
Limitations: Heterogeneous treatments and a lack of large randomized trials. Population: systematic review; 45 studies included out of 3,853 records. Read: abstract.
Declared conflicts of interest: Not visible in the abstract consulted

Written by: AI-assisted literature research (ChatGPT) and AI-assisted writing (Claude)
Editor: Jean Viry-Babel
Review status: Clinical review: Dr Françoise Charmoillaux (anesthesiologist)
Approved on: 9 November 2026
Literature search: 8 November 2026
Last verified: 8 November 2026
Geographic scope: international, United States, France, United Kingdom, Canada
Audience: children and adolescents
Conflicts of interest: No known financial ties. Separately, the publisher is developing a personal approach to these conditions under the name Connected Conditions, which is not cited here (see the legal notice).
Limitations of this page: Pediatric criteria are less well established than adult criteria, especially before age 12, and follow-up studies have limited response rates. Reviewed by an anesthesiologist; not reviewed by a pediatrician.